Share on linkedin

Sands Capital Names Ian Ratcliffe to Executive Management Team

Ian has been instrumental in the development of the venture and private life sciences investing programs. His selection to the leadership team comes as Sands Capital continues to build its private market capabilities.

Contributors

Executive Managing Partner
Executive Managing Director

off

September 2021

Sands Capital appointed Ian Ratcliffe, a 25-year veteran of life sciences technology investing and a current managing partner in its private markets business to its executive management team, which provides strategic leadership across the firm.

Ian’s appointment comes as Sands Capital continues to build its private market capabilities, which range from early-stage venture capital through initial public offering. Through three private growth strategies, the firm partners with emerging and later-stage technology businesses, as well as life sciences businesses that are changing the way diseases are defined, diagnosed, and treated. The firm recently closed Life Sciences Pulse Fund II, its second private life sciences focused fund and a strategy that Ian co-leads.

Ian joined Sands Capital in January of 2016, after many years of collaborating with the team on life sciences investments. He was instrumental in developing the firm’s venture and private life sciences investing programs. He also played a critical role in sourcing many portfolio businesses that enable and build on rapid digitalization and continued advancements in computing power that have the potential to drastically change the way we work and live.

“Ian has a true passion for innovation investing, and especially for investing in life science companies that improve and save lives,” said Frank M. Sands, the firm’s chief executive and chief investment officer, who studied with Ian at University of Virginia’s Darden School. “This has earned him the wide admiration and trust of his colleagues and made him an effective and impactful leader. “

Before joining Sands Capital, Ian launched, expanded, ran, and sold many businesses in the life sciences space, including some involved in cell signaling and gene sequencing. He has a degree in chemical engineering from the University of Surrey and is a graduate of the University of Virginia’s Darden School.

Disclosures:

Sands Capital operates its business primarily through two affiliates: Sands Capital Management, LLC, which provides investment strategies focused on making investments in leading growth companies in the public markets and Sands Capital Ventures, LLC, which provides its clients with investment strategies focused on making venture capital and growth equity investments in leading growth companies in the private markets.

More News & Events

Announcements
Shaping a More Ethical Future for a Digital World
As responsible stewards of client capital, we must encourage corporations to set clear guidelines for appropriate data use.
Announcements
Sands Capital Closes $560 Million Life Sciences Fund
This is Sands Capital’s second life sciences-dedicated fund, and the team will continue investing with an emphasis on private therapeutics, diagnostics, and life sciences tools businesses.
Announcements
Sands Capital Earns High Marks for Responsible Investment Practices
Firm achieves all A scores in 2020 PRI assessment report.
Perspectives Newsletter
Our latest thinking on innovation investing, long-term capital, and culture.

Something has gone wrong, check that all fields have been filled in correctly. If you have adblock, disable it.

The form was sent successfully